Willie Gilbert
Internal Medicine · Cartersville, GANPI 1861804205
Payments from drug & device makers
Across 135 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$528
- Johnson & Johnson$189
- Otsuka America Pharmaceutical, Inc.$163
- Gilead$127
- Exact Sciences$115
- plus $803 from 17 others
What the payments were for
- Food & beverage$3,097100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $1,172 |
| AstraZeneca | 18 | $528 |
| Johnson & Johnson | 5 | $189 |
| Otsuka America Pharmaceutical, Inc. | 7 | $163 |
| Gilead | 2 | $127 |
| Exact Sciences | 6 | $115 |
| Novo Nordisk | 1 | $92 |
| Shield Therapeutics Inc | 4 | $88 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Boehringer Ingelheim | 3 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Pfizer | 3 | $57 |
| GSK | 3 | $54 |
| Lilly USA, LLC | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Amgen | 3 | $44 |
| Insulet Corporation | 2 | $41 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,097 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $102,778 |
| JardianceEmpagliflozin | 80 | $61,352 |
| FarxigaDapagliflozin Propanediol | 65 | $59,127 |
| RybelsusSemaglutide | 29 | $46,122 |
| MounjaroTirzepatide | 35 | $44,062 |
| VraylarCariprazine Hcl | 30 | $42,852 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $37,179 |
| JanuviaSitagliptin Phosphate | 26 | $35,493 |
| EliquisApixaban | 24 | $26,539 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $13,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,099 |
| Gvoke Hypopen 2-PackGlucagon | 17 | $11,658 |
| TrulicityDulaglutide | 12 | $11,230 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,049 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $92 | $148,900127 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $528 | $103,818125 claims |
| Boehringer IngelheimJardiance, Tradjenta | $62 | $68,27793 claims |
| Lilly USA, LLCMounjaro, Trulicity | $52 | $55,29247 claims |
| AbbVieVraylar, Linzess | $1,172 | $48,92341 claims |
| PfizerEliquis | $57 | $26,53924 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $54 | $21,14930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Cartersville
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.